Vivos Therapeutics logo
Vivos Therapeutics VVOS
$ 1.15 -3.36%

Quarterly report 2025-Q3
added 11-19-2025

report update icon

Vivos Therapeutics Financial Statements 2011-2026 | VVOS

Annual Financial Statements Vivos Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

14.3 M 5.89 M 322 K 70.9 B 116 M - - - - - - - - -

Shares

5.02 M 1.22 M 921 K 21.2 B 17.7 M - - - - - - - - -

Historical Prices

2.85 4.83 0.35 3.34 7.51 - - - - - - - - -

Net Income

-11.1 M -13.6 M -23.8 M -20.3 M -12.1 M -10.8 M -8.44 M - - - - - - -

Revenue

15 M 13.8 M 16 M 16.9 M 13.1 M 11.4 M 3.79 M - - - - - - -

Cost of Revenue

6.01 M 5.53 M 200 K 400 K 100 K 2.74 M - - - - - - - -

Gross Profit

9.02 M 8.27 M 10 M 12.6 M 10.4 M 8.66 M 2.71 M - - - - - - -

Operating Income

-11.2 M -17.3 M -25 M -20.4 M -12 M -10.6 M - - - - - - - -

Interest Expense

-110 K -212 K -190 K 14 K 96 K 138 K - - - - - - - -

EBITDA

-10.6 M -16.7 M -24.4 M -19.6 M -7.99 M -9.83 M -7.73 M - - - - - - -

Operating Expenses

20.2 M 25.6 M 35 M 33 M 19.1 M 19.2 M 11 M - - - - - - -

General and Administrative Expenses

17.9 M 22.5 M 29 M 25.8 M 16.1 M 16.2 M 9.27 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Vivos Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

11 M 9.09 M 8.6 M 5.89 M 6.62 M 3.23 M 2.31 M 1.83 M 1.2 M 1.2 M 991 K 921 K 849 K 21.2 M 21.2 M 23 M 20.8 B 20.7 B 18.2 M 18.2 M 12.5 M 12.5 M 12.5 M 12.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-5.4 M -5.01 M -3.86 M - -2.62 M -1.93 M -3.76 M - -2.09 M -5.53 M -1.7 M - -5.43 M -6.99 M -5.33 M - -5.45 M -4.04 M -3.4 M - -1.81 M -1.41 M -2.58 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

6.78 M 3.82 M 3.02 M - 3.86 M 4.05 M 3.42 M - 3.3 M 3.4 M 3.86 M - 4.25 M 4.18 M 3.46 M - 4.55 M 4.5 M 7.74 K - 21 K 21.7 K 20.9 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

2.85 M 1.71 M 1.51 M - 1.53 M 1.4 M 1.48 M - 1.55 M 1.3 M 100 K - 100 K 100 K 100 K - 100 K 100 K 100 K - 709 K 545 K 780 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

3.94 M 2.11 M 1.51 M - 2.33 M 2.65 M 1.94 M - 1.75 M 2.1 M 2.34 M - 2.5 M 2.59 M 2.37 M - 3.18 M 3.62 M 2.69 M - 2.58 M 2.73 M 2.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-4.73 M -4.86 M -3.92 M - -2.64 M -1.94 M -3.78 M - -3.64 M -4.52 M -5 M - -5.41 M -6.96 M -6.82 M - -5.5 M -4.06 M -3.41 M - -1.82 M -1.42 M -2.56 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

500 K -163 K -4 K - -18 K -22 K -1 K - -53 K -225 K 51 K - -36 K -37 K - - 9.49 K 251 82 - 17 K 18.1 K 43.7 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-4.35 M -4.56 M -3.74 M - -2.5 M -1.79 M -3.64 M - -3.49 M -4.37 M -4.83 M - -5.23 M -6.8 M -6.78 M - -4.94 M -3.69 M -3.23 M - -1.64 M -1.24 M -2.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

8.67 M 6.98 M 5.43 M - 4.98 M 4.59 M 5.72 M - 5.39 M 6.62 M 7.34 M - 7.9 M 9.55 M 9.19 M - 8.69 M 7.68 M 6.1 M - 4.4 M 4.14 M 4.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

7.88 M 6.41 M 4.89 M - 4.49 M 4.12 M 4.92 M - 4.6 M 5.88 M 6.54 M - 6.62 M 7.69 M 8.28 M - 6.52 M 6.09 M 5.06 M - 3.79 M 3.46 M 4.23 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Vivos Therapeutics VVOS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Vivos Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.55 -2.31 % $ 73.5 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 88.57 -0.65 % $ 18 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 10.93 -5.12 % $ 1.64 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.4 4.21 % $ 41.1 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 208.22 -4.53 % $ 14.6 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 34.58 -5.62 % $ 1.07 B usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.59 -1.18 % $ 32.1 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.15 -5.29 % $ 3.36 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 79.34 -3.36 % $ 46.4 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.2 -1.84 % $ 1.51 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.52 -5.08 % $ 364 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA
Myomo Myomo
MYO
$ 0.7 2.32 % $ 29.3 M usaUSA
Penumbra Penumbra
PEN
$ 335.1 -0.39 % $ 13 B usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 50.13 -0.63 % $ 1.47 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.17 -5.65 % $ 47.6 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
STRATA Skin Sciences STRATA Skin Sciences
SSKN
- - $ 6.6 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 3.82 -1.04 % $ 106 M australiaAustralia
AxoGen AxoGen
AXGN
$ 31.28 -3.01 % $ 1.44 B usaUSA